With an increasingly clear signal of clinical benefit arising from seven randomized controlled trials of thrombectomy for large vessel occlusion in acute ischaemic stroke, (1) (2) (3) (4) (5) we are at a crossroads in the organization of stroke care. Essential elements are rapid identification of stroke at the first point of contact; triage according to severity and onset time; activation of team including stroke physician and neurointerventionalist; brain imaging and treatment with intravenous (IV) thrombolysis if eligible, with seamless progression into vessel imaging; and transfer of the patient to the treating facility. All with extreme urgency.
Most costs will arise from service structuring issues. Device costs are relatively modest in terms of the potential healthcare gains but staffing a sustainable rota carries high overheads. Redirection of large numbers of patients to facilitate treatment of just a few may not appear to be cost-effective. Only 15-20% of stroke patients receive IV thrombolysis at the most active centers, and fewer than 30% of IV thrombolysis cases progress to thrombectomy.
We must look beyond these challenges, not to the future but the past.
Recent decades have seen specialist stroke units established across many developed countries. Benefits accruing from this multidisciplinary care are substantial, giving absolute gains of around 10% in death and disability. All subgroups of patients gain; however, the benefits are much greater (P = 0·002) among patients with severe stroke, in whom odds ratios for avoiding institutionalization or death are 2·08 [95% confidence interval (CI): 1·43, 3·03] and for avoiding dependency or death are 3·13 (95% CI: 1·96, 5·00) (6). This is supplemented by benefits of IV thrombolysis with alteplase, initiated as early as possible, within 4·5 h. There is no loss of alteplase efficacy with increasing stroke severity: the odds ratio for achieving excellent outcome (modified Rankin Scale 0-1) is 1·50 (95% CI:1·03-2·17) for patients with baseline National Institutes of Health Stroke Scale (NIHSS) score of 16-21 and 3·25 (95% CI:1·42-7·47) for patients with baseline NIHSS score scores above 21 (7). Now, we can add that patients with median NIHSS around 16 can be substantially improved by urgent endovascular treatment (1-5).
Our conclusion must be that patients with severe stroke should be moved swiftly to a specialist comprehensive stroke unit that offers endovascular treatment 24/7. Less severely affected patients may either be managed locally, also in specialist care offering thrombolysis, or included in the central facility depending on capacity. However, it seems only a matter of time before the lower threshold of severity shifts downward, as technology, skills, and trials demonstrate that this is effective, and that capacity will increase.
In 10 years, thrombolysis rates for UK hospitals have risen 20-fold and most achieve rates of 10-20% of eligible patients. The need to deliver thrombolysis helped to encourage organization of specialist stroke services. Past claims that large benefits would apply to only a few patients are no longer valid: the population gains are now substantial. Even so, alongside the benefits from thrombolysis among the minority, all patients gained from the specialist care. This will be extended when we reorganize to offer thrombectomy: it may start as a trickle that applies to a fortunate few, but over time all stroke patients will benefit.
We have to establish a 24/7 thrombectomy service in our major hospitals; however, we will need to consider compromises. Staffing the endovascular service will present a challenge to all but the largest, probably privately funded, services. Can we afford to have cardiologists perform percutaneous coronary interventions for myocardial infarction independently from neurointerventionalists performing thrombectomy for ischaemic stroke, or should we plan toward a common vascular intervention service? There are undoubtedly many subtle and important aspects to delivering optimal thrombectomy that only an experienced neurointerventionalist can offer. These may improve individual patients' outcomes but perhaps population benefits may be greater by delivering treatment less expertly but more quickly and comprehensively through a joint approach with our cardiological colleagues. Some have described good experience (8) . These questions need local solutions.
There are developing countries that still have few stroke units and countries with patchy stroke services where national thrombolysis rates for suitable patients are under 0·1%. Organizing specialist stroke care for all must be their priority. It will benefit the severe stroke patients too, and by as much as thrombectomy. These centers can readily add IV thrombolysis, and for relatively limited cost, they can accelerate their door-to-needle times, achieving moderate population benefits (9) .
For urban centers in developed countries, thrombectomy needs to be implemented as soon as possible, but let's not forget that this is the icing on the cake, because the real nutritional value is in its stroke unit base and thrombolysis filling. Let them eat cake!
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